At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 78 target
Drug / intervention
Belzutifan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
In Brief
A Phase 2 clinical trial evaluating Belzutifan and Active Surveillance for Active Surveillance and Clear Cell Renal Cell Carcinoma. Currently recruiting, targeting 78 participants across 1 site.
Detailed Summary
To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not undergone previous systemic treatment. The safety of belzutifan in this patient population will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2Recruiting
20262027202820292030
First PostedJun 2025
Enrollment StartNov 2025
TodayJul 2026
Primary CompletionApr 2028
Study CompletionApr 2030
First PostedJun 17, 2025
Enrollment StartNov 17, 2025
Primary CompletionApr 14, 2028
Study CompletionApr 14, 2030
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 1.0 years agoPrimary completion in 1.8 years
Interventions
Belzutifandrug
Given by PO
Active Surveillanceother
Given by Observation